



GlycoTreat Secures Strategic Investment from Dactari to Accelerate Breakthrough Allergy Immunotherapy

Amersfoort, The Netherlands – 12 August 2025. GlycoTreat, a pioneering biotechnology company developing immunotherapies for chronic allergic conditions, today announced the successful closing of an investment from Dactari Dierenartsencoöperatie, a fund dedicated to advancing innovation in the veterinary sector.

Founded by Ina Margaretha Rijnhout (CEO) and Prof. Yvette van Kooyk (CSO), internationally renowned immunologist and recipient of the prestigious Spinoza Award, GlycoTreat is building a first-in-class glyco-immunology technology platform that reprograms the immune system to restore tolerance.

"Our mission is ambitious yet focused: pursuing a cure for allergic conditions through precision immunotherapy," said Ina Margaretha Rijnhout, CEO of GlycoTreat. "With Dactari's support and deep understanding of veterinary practice, we are gaining a partner equally committed to transforming medical care for animals. This milestone empowers us to advance our lead program in Canine Allergic Dermatitis toward clinical validation."

The company's approach centers on tolerogenic glycans inducing long-lasting immune tolerance. By targeting the underlying cause of allergies, GlycoTreat's GlycoTx™ platform offers a potentially curative alternative to symptomatic treatments.

"GlycoTreat brings forward a transformative scientific vision that perfectly aligns with our mission to support innovations that take the work of veterinarians to the next level," said Marco Labordus of Ons Dactari Fonds. "We believe their approach has the potential to significantly improve animal health outcomes and strengthen the future of veterinary medicine."

Ons Dactari Fonds invests in initiatives that promote, improve, or innovate the veterinary profession. Their investment in GlycoTreat represents a strong vote of confidence in the platform's veterinary potential and its relevance across species.

With this funding, GlycoTreat is actively expanding its collaborations with academic institutions and pharmaceutical partners, aiming to bring the next generation of allergen-specific immunotherapies to clinical application in both humans and animals.

Contact:

Ina Margaretha Rijnhout, CEO | irijnhout@glycotreat.com | www.glycotreat.com | <https://www.linkedin.com/company/glycotreat/>